Table 3. Observed reductions in Schistosoma infection intensity in selected field studies.
Study [citation] | Country Location | Study Size | Diagnosed with | Local Pre-treatment Prevalence | Two Dose Interval | Follow up interval | One Dose-Any Intensity | One Dose-Light Infections | One Dose-Heavy Infections | Two Doses-Any Intensity | Two Doses-Light Infections | Two Doses-Heavy Infections |
Reported reduction in Schistosoma mansoni infection intensity | ||||||||||||
Barakat, 2010s [12] | Egypt | 588 | 1 stool, KK | 44% | 4 weeks | 4 weeks | 71% | 34% | 87% | 74% | 34% | 89% |
Utzinger, 2000s [21] | Cote d'Ivoire | 253 | 4 stools KK | 77% | 5 weeks (60 mg/40 mg) | 4 weeks | 80% | 89% | ||||
Black, 2009a [13] | Kenya | 178 | 3 stools KK | 83% | 6 weeks | 4–6 weeks | 83% (62–91%) | |||||
Picquet, 1998c [18] | Senegal | 113 | 1 stool, KK | 87% | 6 weeks | 4 weeks | 71% | 30% | 88% | 88% | 56% | 96% |
Kabatereine 2003c [14] | Uganda | 617 | 3 stools KK | 92% | 6 weeks | 6 weeks | 98% | 99.6% | ||||
Reported reduction in S. haematobium infection intensity | ||||||||||||
Midzi, 2008s [16] | Zimbabwe | 675 | 3 urines, filtration | 51% | 6 weeks | 4 months | 94% | |||||
Mduluza, 2001s [15] | Zimbabwe | 595 | 3 urines, filtration | 52% | 8 weeks | 8 weeks | 96% | 92% | ||||
Tchuem-Tchuente, 2004s [20] | Cameroon | 515 | 2 urines, filtration | 42% | 3 weeks | 6 weeks | 98% | 98% | 99% | 99% | 98% | 99.7% |
N'goran, 2003s [17] | Cote d'Ivoire | 354 | 4 urines, filtration | 77% | 4 weeks | 3 weeks | 97% | |||||
Sacko, 2009s - [19] Selingue | Mali | 256 | 3 urines, filtration | 87% | 2 weeks | 3 months | 99% | 99% | ||||
Sacko, 2009s - [19] Koulikoro | Mali | 300 | 3 urines, filtration | 95% | 2 weeks | 3 months | 98% | 99% |
Study based on school age participants only;
Study based on adults only;
Community-based study.